Table 1.

Clinicopathologic details of 17 patients with NSCLC with FGFR fusions

IHC score
Patient No.Age, ySexSmoking (pack-years)StageTumor size (cm)Lymph node statusHistologyDifferentiationFGFR fusionFGFR1FGFR3aFGFR3cP40TTF1Subtype
148M30II B8.0N1SCCWellFGFR3-TACC3*+
270M40I B3.20SCCModerateFGFR3-TACC3Δ+++
349M20III A4.0N2SCCModerateFGFR3-TACC3Δ++
455M30III A5.0N2SCCPoorFGFR3-TACC3°+++
555M45II A2.0N1SCCPoorFGFR3-TACC3+++
665M40I B5.00SCCPoorFGFR3-TACC3*++++
762M45II B6.0N1SCCPoorFGFR3-TACC3+++
862M35II B8.00SCCModerateFGFR3-TACC3+++
946M40I A3.00SCCModerateFGFR3-TACC3Δ++
1075M50II A4.0N1ADPoorFGFR3-TACC3Δ+++Solid
1164M40III A3.5N2ADPoorFGFR3-TACC3Δ+++Papillar + solid
1256M5I B4.00ADModerateFGFR3-TACC3Δ+++Acinar
1352M60I B5.00ADModerateFGFR3-TACC3Δ++Solid
1462M35II A6.00ADPoorFGFR3-TACC3Δ++Acinar + solid
1545F0III A4.0N2ADPoorFGFR3-TACC3Δ++Solid
1661M40II B5.50SCCModerateBAG4-FGFR1+++
1748M105I B4.00SCCPoorBAG4-FGFR1+++

Abbreviation: AD, adenocarcinoma.

FGFR3-TACC3*, FGFR3-TACC3 (E18:E11 INS78 bp intron from TACC3).

FGFR3-TACC3Δ, FGFR3-TACC3 (E17:E11).

FGFR3-TACC3°, FGFR3-TACC3 (E17:E8).

FGFR3-TACC3♀, FGFR3-TACC3 (E17:E5 INS71 bp intron from TACC3).

FGFR3-TACC3♂, FGFR3-TACC3 (E17:E10).

BAG4-FGFR1, BAG4-FGFR1 (E1:E8).

FGFR3(a): FGFR3 antibody from Abcam.

FGFR3(c): FGFR3 antibody from Cell Signaling Technology.